Genentech Tries to Calm Cabilly Worries

 

Genentech (DNA) said the U.S. Patent and Trademark Office issued an initial action on Sept. 13 rejecting the claims of what's known as the "Cabilly" patent, but the biotech company added that it remains valid and enforceable while a re-examination is pending.

The move was "a routine and expected next step" in the process, Genentech said in a press release issued early Wednesday. The company plans to respond to the decision within 60 days of its mailing date.

The patent office action came about after another party asked for a re-examination of the patent in May. Genentech said the final resolution of the re-examination might take anywhere from several months to several years.

Genentech, based in South San Francisco, Calif., licenses the patent to other companies and collects royalties from those agreements. Examples of Genentech products that use the technology covered in the patent include the breast cancer treatment Herceptin and the non-Hodgkin's lymphoma drug Rituxan.

The patent in the matter was first filed in 1983, when Celltech filed an application in the U.K. that dealt with the methods used to produce antibodies by recombinant DNA technology. Celltech submitted a similar filing in the U.S. for what came to be called the "Boss" patent, after Michael Boss and other inventors.

That same year, Genentech filed an application on a similar patent, known as the Cabilly patent for inventor Shmuel Cabilly and others.

Celltech and Genentech eventually became involved in a dispute that lasted for several years but has now been settled. As a result of that agreement, Genentech received a new patent in 2001 that isn't set to expire until 2018. Prior to the agreement, the old Cabilly patent and the Boss patent, both granted in 1989, were due to expire in 2006.

TheStreet Premium Services    For Personal Service: 877-471-2967

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
New: ETF Profits
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Doug Kass
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,801.23 1,342.64 2,903.88 19.69
Oil *
117.67
DOWN
89.23
DOWN
9.31
DOWN
23.35
DOWN
0.78
10 Yr
1.97%
SPDR Gold
167.14
-0.69%
-0.69%
-0.80%
-3.81%
Data delayed 20 minutes

Top Stories and Tools

Brokerage Partners

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet